FDA Aims To Boost Transparency Through Earlier Release Of Panel Materials
This article was originally published in The Tan Sheet
Executive Summary
FDA will post advisory committee briefing materials on its Web site at least two business days in advance of meetings, doubling the current lead time in an effort to enhance transparency, according to a Feb. 28 draft guidance
You may also be interested in...
Advocacy For Drug Safety And Public Health Loses Passionate And Effective Leader Sidney Wolfe
Wolfe is lauded by former colleagues for his fierceness in pushing to get dangerous drugs off the market, his rigorous scientific approach, and mastery of the press.
Public Citizen’s Wolfe Joins FDA Advisory Committee
FDA's Drug Safety and Risk Management Advisory Committee will be a tougher venue for drug sponsors during the next four years - long-time consumer advocate Sidney Wolfe recently was named a permanent committee member
FDA Embraces Controversy Among Reasons To Convene Advisory Committees
Applications for Rx-to-OTC switches will continue to be reviewed in advisory committee meetings because they often meet FDA's reasons to seek an advisory panel's recommendation under a proposed guidance